Item 2.02 Results of Operations and Financial Condition.
The information in Item 2.02 of this Current Report on Form 8-K, including the
preliminary financial results for the quarter ended
Item 8.01 Other Events.
On
The Company has updated its disclosures. The disclosures are filed herewith as Exhibit 99.2 and are incorporated by reference herein.
This Current Report on Form 8-K contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995, including but
not limited to, statements regarding: the Company's preliminary financial
results; the impact of COVID-19 on the Company's business and the actions it may
take in response thereto; the Company's strategy; the Company's business plan,
including expectations regarding future partnerships, acquisitions and networks;
the Company's beliefs with respect to the size of the total addressable markets
for its tests; the Company's beliefs with respect to the effect of its expertise
and technology in the medical industry; future growth and the keys to such
growth; the expected benefits from past and future acquisitions; continued
investment in the Company's business; future operations; future operating
results and expense levels; and the prospects, plans and objectives of
management. The Company has based these forward-looking statements on its
current expectations and projections about future events and trends that the
Company believes may affect its financial condition, results of operations,
strategy, short- and long-term business operations and objectives, and financial
requirements. Forward-looking statements are subject to known and unknown risks,
uncertainties and assumptions that could cause actual results to differ
materially, and reported results should not be considered as an indication of
future performance. These risks and uncertainties include, but are not limited
to: the completion of the quarter and the quarterly close process and 2020
audit; the effect of the COVID-19 pandemic on the Company's business and the
success of any measures it has taken or may take in the future in response
thereto; risks associated with the Company's ability to develop and
commercialize new tests and expand into new markets; the Company's ability to
use rapidly changing genetic data to interpret test results accurately,
consistently and quickly; the Company's history of losses; the Company's need to
scale its infrastructure in advance of demand for its tests and its ability to
increase demand for its tests; the Company's ability to drive revenue; the
impact of current and future litigation on the Company's business; the Company's
ability to integrate and scale acquired businesses and realize the intended
benefits of such acquisitions; the risk that the Company may not obtain or
maintain sufficient levels of reimbursement for its tests; the ability of the
Company to obtain required regulatory approvals for its tests; laws and
regulations applicable to the Company's business, including potential regulation
by the
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits. 99.1 Press Release datedJanuary 20, 2021 . 99.2 Disclosures. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
--------------------------------------------------------------------------------
© Edgar Online, source